Routine and habits
Micro-Athlete heart-on-a-chip simulates
Researchers have developed a 'Micro-Athlete' platform using stem-cell-derived heart tissue on a chip to mimic exercise, aiming to study exertion-related
Routine and habits
Routine and habits on Night and Rest.
Routine and habits
Orexin Agonist Oveporexton Approved for Narcolepsy Type 1
ORZEYFUL (oveporexton), the first oral orexin receptor 2 agonist, has received regulatory approval in Japan, the US, and China for treating narcolepsy type
Routine and habits
AI May Help Identify Breast Cancers Missed by Mammograms
A review led by UCLA Health Jonsson Comprehensive Cancer Center investigates AI's potential to detect interval breast cancers missed by routine mammograms
Routine and habits
TOMAC Therapy for Restless Legs Syndrome
Tonic motor activation (TOMAC) is a noninvasive, wearable electrical stimulation therapy for moderate to severe restless legs syndrome.
Routine and habits
Psilocybin therapy faces palliative care
A Canadian survey finds most palliative care professionals favor psilocybin therapy for end-of-life distress but feel ill-informed and cite a shortage of
Routine and habits
Sweden: Temp extremes up heart failure risk
A study links short-term exposure to cold spells and heat with higher heart failure hospitalizations in Sweden, stressing timely clinical response.
Routine and habits
The Exhausting Beach Day: Uncovering the Physiological Efforts Behind Relaxation
Spending a day at the beach can be surprisingly exhausting, despite appearing to be a relaxing activity. Experts explain the physiological mechanisms behind this phenomenon, including thermoregulation, fluid loss, and defense against solar radiation.
Routine and habits
Breakthrough in Bone Implant Technology Saves Patient's Leg
A team of doctors and engineers from the Hospital Gregorio Marañón and the Universidad Politécnica de Madrid have successfully implanted a customized bone implant made from a 3D printed titanium metamaterial, saving a patient's leg from amputation.
Routine and habits
DEA Proposes Rescheduling DORAs for Insomnia Treatment
The US Drug Enforcement Administration (DEA) has proposed transferring three dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V of the Controlled Substances Act.